Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Neurocrine Biosciences, Inc. - Common Stock
(NQ:
NBIX
)
133.51
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Neurocrine Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Today 8:00 EDT
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
Via
Investor's Business Daily
Topics
Intellectual Property
A Glimpse Into The Expert Outlook On Neurocrine Biosciences Through 14 Analysts
July 09, 2025
Via
Benzinga
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuation
July 09, 2025
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it an interesting candidate for investors seeking affordable growth stocks in the biotech...
Via
Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential
July 04, 2025
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch. High profitability, no debt, and a potential breakout add to its appeal.
Via
Chartmill
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
June 29, 2025
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Analyst Expectations For Neurocrine Biosciences's Future
June 02, 2025
Via
Benzinga
Earnings Scheduled For May 5, 2025
May 05, 2025
Via
Benzinga
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Promising Affordable Growth Stock
June 18, 2025
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive candidate for investors seeking affordable growth in the biotech sector.
Via
Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential
June 12, 2025
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth, profitability, and a bullish technical setup, making it a stock worth watching for growth investors.
Via
Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuation
May 28, 2025
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it a candidate for investors seeking affordable growth stocks in the biotech sector.
Via
Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential
May 21, 2025
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth fundamentals and a promising technical setup, making it a stock to watch for potential breakout opportunities.
Via
Chartmill
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
May 06, 2025
Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes.
Via
Benzinga
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug
May 06, 2025
The company reported a strong start for its newest drug, Crenessity, which treats a hormonal disorder involving the adrenal glands.
Via
Investor's Business Daily
FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday
May 06, 2025
Via
Benzinga
What 19 Analyst Ratings Have To Say About Neurocrine Biosciences
May 06, 2025
Via
Benzinga
Neurocrine Biosciences Stock Surges After-Hours On Upbeat Q1, Reaffirmed Ingrezza Outlook — Retail Buzz Soars
May 05, 2025
CEO Kyle Gano highlighted record new patient starts for Ingrezza and noted positive early response to the launch of Crenessity, positioning the company for sustained growth.
Via
Stocktwits
12 Health Care Stocks Moving In Monday's After-Market Session
May 05, 2025
Via
Benzinga
Top movers in Monday's after hours session
May 05, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is not too expensive for the growth it is showing.
May 05, 2025
Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an...
Via
Chartmill
What to Expect from Neurocrine Biosciences's Earnings
May 02, 2025
Via
Benzinga
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Stock
May 01, 2025
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Stock
Via
Chartmill
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?
April 20, 2025
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.
Via
Benzinga
Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish
April 15, 2025
Physician survey shows high uptake of Neurocrine Biosciences' Crenessity for patients with CAH.
Via
Benzinga
What 16 Analyst Ratings Have To Say About Neurocrine Biosciences
April 15, 2025
Via
Benzinga
This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
April 15, 2025
Via
Benzinga
Looking for growth without the hefty price tag? Consider NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
April 11, 2025
Based on Fundamental Analysis it can be said that NASDAQ:NBIX is a growth stock which is not overvalued.
Via
Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is an undervalued gem with solid fundamentals.
April 09, 2025
Discover NEUROCRINE BIOSCIENCES INC, an undervalued stock. NASDAQ:NBIX showcases solid financial health and profitability while maintaining an appealing valuation.
Via
Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—A High-Growth Stock Gearing Up for Its Next Upward Move.
March 27, 2025
Based on a technical and fundamental analysis of NASDAQ:NBIX we can say: NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via
Chartmill
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
March 26, 2025
Via
The Motley Fool
Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings)
March 26, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.